Cargando…
Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway
Recent studies have suggested that liraglutide could have a potential function in improving non-alcoholic fatty liver disease (NAFLD); however, the underlying molecular mechanism remains unclear. The aim of the present study was to investigate the role of the AMP-activated protein kinase (AMPK)/ster...
Autores principales: | WANG, YAN-GUI, YANG, TIAN-LUN |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665609/ https://www.ncbi.nlm.nih.gov/pubmed/26640549 http://dx.doi.org/10.3892/etm.2015.2741 |
Ejemplares similares
-
Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway
por: Wang, Yan-Gui, et al.
Publicado: (2015) -
Nifedipine Modulates Renal Lipogenesis via the AMPK-SREBP Transcriptional Pathway
por: Lin, Yen-Chung, et al.
Publicado: (2019) -
Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling
por: Tang, Hong, et al.
Publicado: (2016) -
Liraglutide Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism via SHP1/AMPK Signaling Pathway
por: Yu, Peng, et al.
Publicado: (2019) -
Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway
por: Zhou, Rui, et al.
Publicado: (2021)